<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	xmlns:unherd="https://www.unherd.com"
	>

	<channel>
		<title>Margaret McCartney, a writer for UnHerd</title>
		<atom:link href="https://stage.unherd.com/author/margaretmccartney/feed/" rel="self" type="application/rss+xml" />
		<link>https://stage.unherd.com/author/margaretmccartney/</link>
		<description>think again</description>
		<lastBuildDate>Sat, 03 Jan 2026 23:52:37 +0000</lastBuildDate>
		<language>en-US</language>
		<sy:updatePeriod>hourly</sy:updatePeriod>
		<sy:updateFrequency>12</sy:updateFrequency>
		<generator>https://wordpress.org/?v=7.1.5</generator>

<image>
	<url>https://stage.unherd.com/wp-content/uploads/2019/09/cropped-favicon.jpg?w=32</url>
	<title>Margaret McCartney, a writer for UnHerd</title>
	<link>https://stage.unherd.com/author/margaretmccartney/</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">241382538</site>				<item>
					<title>Google AI’s health advice is undermining doctors</title>
					<link>https://stage.unherd.com/newsroom/google-ais-health-advice-is-undermining-doctors/?edition=us</link>
											<comments>https://stage.unherd.com/newsroom/google-ais-health-advice-is-undermining-doctors/?edition=us#comments</comments>
										<unherd:featured_image>https://stage.unherd.com/wp-content/uploads/2026/01/GettyImages-71205638.jpg?w=525</unherd:featured_image>
										<unherd:main_theme></unherd:main_theme>
					<dc:creator>
						<![CDATA[Margaret McCartney]]>
					</dc:creator>
					<unherd:creator_img>https://stage.unherd.com/wp-content/uploads/2024/02/blued-margaret-300x300-1.jpg?w=96</unherd:creator_img>
																									<unherd:author_bio>
						<![CDATA[ is a GP and broadcaster.]]>
					</unherd:author_bio>
										<pubDate>Sun, 04 Jan 2026 08:00:30 +0000</pubDate>
					<updated>Sun, 04 Jan 2026 08:00:30 +0000</updated>
							<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[Artificial intelligence]]></category>
		<category><![CDATA[Google]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medicine]]></category>
					<guid isPermaLink="false">https://stage.unherd.com/?post_type=newsroom&#038;p=1043547</guid>
																												<description>
								<![CDATA[Unproven claims are putting patients at risk]]>
							</description>
																		
																			<content:encoded>
								<![CDATA[<p>Artificial intelligence has been <a href="https://www.weforum.org/stories/2025/08/ai-transforming-global-health/" target="_blank" rel="noopener">hailed</a> as the answer to numerous problems in healthcare, ranging from early diagnoses to administrative shortages. Yet it is also increasingly seen as a cause of harm, adding to the existing pile of bad information about disease and treatments. The <i>Guardian</i> has now <a href="https://www.theguardian.com/technology/2026/jan/02/google-ai-overviews-risk-harm-misleading-health-information" target="_blank" rel="noopener">reported</a> that Google’s AI Overviews, which are increasingly appearing at the top of Google searches, are inaccurate and misleading on subjects including liver tests and pancreatic cancer. Google, meanwhile, says it has “a knowledge base of billions of facts” and <a href="https://blog.google/products/search/generative-ai-google-search-may-2024/" target="_blank" rel="noopener">maintains</a> that “the vast majority provide accurate information”.</p>
<p>Many doctors would be delighted for AI to transform their working lives. It would be ideal if, for example, there were checks on whether the people who were meant to have blood tests actually did, with the results consulted and plans for a follow-up put in place. It should be possible to tailor written information about conditions to individual people’s preferences, using varying detail and visual help such as diagrams depending on what people want. GPs receive a huge amount of paperwork every day; filtering out what is urgent and what is not could save hours of time. I am, emphatically, not “against” AI: I am simply against poorly tested AI which makes claims far beyond proof.</p>
<p>The use of AI in healthcare increasingly resembles an inadequately regulated mess which risks misleading patients while making us all stupid. Who could forget Babylon Healthcare, which received millions in funding for an app which used AI to act as a triage system and was supposedly a “GP in your pocket”? In 2018, then-Health Secretary Matt Hancock proudly <a href="https://www.gov.uk/government/speeches/matt-hancock-my-priorities-for-the-health-and-social-care-system" target="_blank" rel="noopener">stated</a> that it “works brilliantly for me”. Despite the scheme’s obvious failings, it was <a href="https://margaretmccartney.substack.com/p/miss-triggs-and-babylon-healthcare" target="_blank" rel="noopener">difficult</a> to convince any regulator to investigate unproven claims about safety measures. Babylon eventually went bust in 2023.</p>
<p>There is clearly a culture clash between medicine and AI. In the former, practitioners are taught to test hypotheses before making claims of effectiveness. This is the only thing that stands between doctors and quackery, medicine having a long history of <a href="https://academic.oup.com/ije/article-abstract/34/4/874/692905?redirectedFrom=fulltext" target="_blank" rel="noopener">avoidable harm</a> to patients. In the muscular world of technology, meanwhile, innovation and branding tend to attract attention, investment and kudos; AI moguls prioritize moving fast and breaking things, while skeptics who demand further evidence are dismissed as ignorant Luddites.</p>
<p>Yet patients and their families who are harmed by bad information often go uncounted in balance sheets. Unless you carry out formal tests of what information people receive, you are risking harms which, if you don’t look for them, you won’t learn from. What’s more, the use of bad AI can stop us thinking for ourselves. I have been horrified by how normalized the use of AI is in university assessments, letters to medical journals, CVs and job applications. Faulty syntax is preferable to recycled ideas, produced with the same template, which dull the fantastic potency of human ideas.</p>
<p>There is no shortage of good health information online, if you know where to look. When AI-powered search engines produce “the facts”, it’s tempting to believe them. Humans crave authority and that requires trust, but what we have at present doesn’t deserve it. Critical-thinking skills are vital for any internet user. It’s good to question what we are told, especially when it comes from “black boxes” where we don’t know the working-out process. AI has the potential to provide huge benefits to those seeking medical assistance, but we need to get our priorities right and test hypotheses first. Bad information can be just as harmful as the side effects from drugs.</p>
<style>
				a.appcomments {
					background: #FFF;
					border: 1px solid #446c76 !important;
					font-family: benton-sans,sans-serif;
					font-weight: 600;
					font-style: normal;
					font-size: 12px;
					color: #446c76 !important;
					padding: 12px 50px;
					text-transform: uppercase;
					letter-spacing: 1.5px;
					text-decoration: none;
					width: 100%;
					display: block;
					text-align: center !important;
				 }
			</style>
			<a href="https://stage.unherd.com/newsroom/google-ais-health-advice-is-undermining-doctors/?edition=us?appcomments" class="appcomments">view comments</a>]]>
							</content:encoded>
																<unherd:comments_embed_url>https://stage.unherd.com/newsroom/google-ais-health-advice-is-undermining-doctors/?edition=us?appcommentsnew</unherd:comments_embed_url>
											<wfw:commentRss>https://stage.unherd.com/newsroom/google-ais-health-advice-is-undermining-doctors/?edition=us/feed/</wfw:commentRss>
															<post-id xmlns="com-wordpress:feed-additions:1">1043547</post-id>				</item>
									<item>
					<title>How increased prostate cancer screening can harm men</title>
					<link>https://stage.unherd.com/newsroom/how-increased-prostate-cancer-screening-can-harm-men/?edition=us</link>
											<comments>https://stage.unherd.com/newsroom/how-increased-prostate-cancer-screening-can-harm-men/?edition=us#comments</comments>
										<unherd:featured_image>https://stage.unherd.com/wp-content/uploads/2025/11/GettyImages-2218456404.jpg?w=525</unherd:featured_image>
										<unherd:main_theme></unherd:main_theme>
					<dc:creator>
						<![CDATA[Margaret McCartney]]>
					</dc:creator>
					<unherd:creator_img>https://stage.unherd.com/wp-content/uploads/2024/02/blued-margaret-300x300-1.jpg?w=96</unherd:creator_img>
																									<unherd:author_bio>
						<![CDATA[ is a GP and broadcaster.]]>
					</unherd:author_bio>
										<pubDate>Tue, 25 Nov 2025 16:00:30 +0000</pubDate>
					<updated>Tue, 25 Nov 2025 16:09:09 +0000</updated>
							<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[David Cameron]]></category>
		<category><![CDATA[NHS]]></category>
		<category><![CDATA[Prostate cancer]]></category>
		<category><![CDATA[PSA test]]></category>
		<category><![CDATA[Science]]></category>
					<guid isPermaLink="false">https://stage.unherd.com/?post_type=newsroom&#038;p=1038645</guid>
																												<description>
								<![CDATA[Overdiagnosis leads to further problems from treatment]]>
							</description>
																		
																			<content:encoded>
								<![CDATA[<p>David Cameron has joined the King as the latest public figure to disclose his diagnosis of prostate cancer. In an <a href="https://www.thetimes.com/life-style/health-fitness/article/david-cameron-interview-prostate-cancer-kmtc2zj78" target="_blank" rel="noopener">interview</a> with the <i>Times </i>this week, the former British prime minister revealed that, after a prostate-specific antigen (PSA) test earlier this year, a biopsy and MRI scan gave him the diagnosis. He has said that he was successfully treated with focal therapy.</p>
<p>While poor media reporting on health issues is nothing new, the rhetoric on prostate cancer screening is persistently terrible and seems now incapable of correcting itself, particularly on the PSA blood test.</p>
<p>Prostate cancer is common — <a href="https://prostatecanceruk.org/prostate-information-and-support/risk-and-symptoms/about-prostate-cancer" target="_blank" rel="noopener">roughly</a> one in eight men will get it in their lifetime — and a blood test is widely publicized as a quick and easy way to find it. It’s therefore often asked: why aren’t men being offered this on a large scale, and just getting the test to see if they have it? Media outlets then say men should ask for one, hinting, perhaps darkly, that more should be done by the NHS with regard to male health. The UK National Screening Committee is now being <a href="https://www.theguardian.com/society/2025/nov/25/what-is-prostate-cancer-and-how-is-it-diagnosed-in-the-uk" target="_blank" rel="noopener">placed</a> under immense pressure to recommend some kind of prostate cancer screening for those at highest risk of suffering from the condition.</p>
<p>Yet this increased screening could cause problems. There is a phenomenon known as the “popularity paradox”. The PSA blood test will find lots of “abnormalities” as it looks for levels of the PSA protein in blood samples, which could indicate the presence of prostate cancer. People who have been tested and have been told they have abnormalities tell others that they should test, and this happens <i>ad infinitum</i>. And so more get tested, and more abnormalities are found. And it seems that far, far more people who have abnormalities are found than those who die from the disease. Taken together, this makes it look as though the testing is working and that we are finding and potentially helping more people when, in fact, the test is really picking up many “abnormalities” which are not going to become harmful.</p>
<p>This is the problem with prostate cancer screening and the current campaigns for it. Outlets consistently publish stories about politicians and celebrities who have had the test, found abnormalities, and may have found cancer. And because it is not a routine offer made to men in the NHS, the recommendation is usually that they should be prepared to “fight” to have it done. But does this approach do men any favors?</p>
<p>Proponents of screening think they are doing a good thing — of course, people want to do something to help when feeling powerless over a disease that can be aggressive and difficult to treat. But given we know that prostate cancer, left alone, often does not affect male lifespans, we should be careful that we are not just putting up diagnosis rates without actually stopping men from dying of prostate cancer.</p>
<p>The risk is that low-risk men have PSA screening and — several scans, biopsies and treatments later — end up with lifelong complications from treatment they didn’t need, as the cancer may not have caused them any serious harm alongside the risk that the test still doesn’t perform well enough to stop aggressive cancers from causing deaths. NHS rules are, as I write, that men can make an informed choice to have the PSA test. A large trial, <a href="https://prostatecanceruk.org/research/transform-trial" target="_blank" rel="noopener">TRANSFORM</a>, should hopefully work out whether the PSA test, plus MRI scans, can limit the harms and maximize the benefits in a way that might make it a reasonably good screening test. But we are not there yet and, in the meantime, men deserve to have good health information rather than misleading claims and hype.</p>
<style>
				a.appcomments {
					background: #FFF;
					border: 1px solid #446c76 !important;
					font-family: benton-sans,sans-serif;
					font-weight: 600;
					font-style: normal;
					font-size: 12px;
					color: #446c76 !important;
					padding: 12px 50px;
					text-transform: uppercase;
					letter-spacing: 1.5px;
					text-decoration: none;
					width: 100%;
					display: block;
					text-align: center !important;
				 }
			</style>
			<a href="https://stage.unherd.com/newsroom/how-increased-prostate-cancer-screening-can-harm-men/?edition=us?appcomments" class="appcomments">view comments</a>]]>
							</content:encoded>
																<unherd:comments_embed_url>https://stage.unherd.com/newsroom/how-increased-prostate-cancer-screening-can-harm-men/?edition=us?appcommentsnew</unherd:comments_embed_url>
											<wfw:commentRss>https://stage.unherd.com/newsroom/how-increased-prostate-cancer-screening-can-harm-men/?edition=us/feed/</wfw:commentRss>
															<post-id xmlns="com-wordpress:feed-additions:1">1038645</post-id>				</item>
									<item>
					<title>Britain needs more than Ozempic to defeat obesity</title>
					<link>https://stage.unherd.com/newsroom/britain-needs-more-than-ozempic-to-defeat-obesity/?edition=us</link>
											<comments>https://stage.unherd.com/newsroom/britain-needs-more-than-ozempic-to-defeat-obesity/?edition=us#comments</comments>
										<unherd:featured_image>https://stage.unherd.com/wp-content/uploads/2025/10/GettyImages-2238275948.jpg?w=525</unherd:featured_image>
										<unherd:main_theme></unherd:main_theme>
					<dc:creator>
						<![CDATA[Margaret McCartney]]>
					</dc:creator>
					<unherd:creator_img>https://stage.unherd.com/wp-content/uploads/2024/02/blued-margaret-300x300-1.jpg?w=96</unherd:creator_img>
																									<unherd:author_bio>
						<![CDATA[ is a GP and broadcaster.]]>
					</unherd:author_bio>
										<pubDate>Thu, 02 Oct 2025 09:00:36 +0000</pubDate>
					<updated>Thu, 02 Oct 2025 09:37:26 +0000</updated>
							<category><![CDATA[GLP-1 drugs]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Obesity]]></category>
		<category><![CDATA[Ozempic]]></category>
		<category><![CDATA[wegovy]]></category>
		<category><![CDATA[weight loss]]></category>
		<category><![CDATA[Wes Streeting]]></category>
					<guid isPermaLink="false">https://stage.unherd.com/?post_type=newsroom&#038;p=1031173</guid>
																												<description>
								<![CDATA[Wes Streeting is placing too much trust in new drugs]]>
							</description>
																		
																			<content:encoded>
								<![CDATA[<p>“Weight-loss jabs could help us <a href="https://labourlist.org/2025/10/labour-conference-2025-wes-streeting-conference-speech-transcript/" target="_blank" rel="noopener">finally defeat</a> obesity,” Health Wes Streeting told the Labour Party conference earlier this week. “The wealthy talk about how they’ve transformed their health, their confidence, their quality of life,” he said. “But […] what about the millions who can’t afford them?” The Streeting “war on obesity” subsequently produced headlines: obesity is the enemy, and the new generation of GLP-1 drugs (such as Wegovy and Ozempic) are our foot soldiers.</p>
<p>Streeting’s point on health inequalities is well made. Numbers of people whose weight is categorized as overweight and obese are steadily rising in the UK, with over a third of 35 to 74-year-olds technically “obese”. The risk is <a href="https://researchbriefings.files.parliament.uk/documents/SN03336/SN03336.pdf" target="_blank" rel="noopener">higher</a> for people who are disabled, or who live in areas of deprivation. There are also a massive number of online pharmacies and clinics which have been offering these drugs on a paid-for basis over the last couple of years, costing a couple of hundred pounds a month all while the NHS has been <a href="https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/" target="_blank" rel="noopener">highly restrictive</a> in prescribing them.</p>
<p>Taken together, this means that the people most likely to benefit from this new group of drugs have been the least able to access them. And given that it’s <a href="https://pubmed.ncbi.nlm.nih.gov/11684524/" target="_blank" rel="noopener">difficult for most people</a> who have lost weight to keep it off in the long term, an effective intervention should be welcome. Medicine has a long history of offering dodgy diet pills from even dodgier clinics, but these new drugs have been through high-quality trials and the NICE approvals process.</p>
<p>Except there is something that bothers me: not simply the echo of the “<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8749321/" target="_blank" rel="noopener">war on cancer</a>” that Richard Nixon announced in 1971, but the aim at obesity as though it is a lone ranger, appearing unexpectedly over the horizon as if from nowhere. The risk factors for obesity are complex, but it is enmeshed with poverty, <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8814640/" target="_blank" rel="noopener">advertising</a> and <a href="https://publications.parliament.uk/pa/cm5803/cmselect/cmenvfru/622/report.html" target="_blank" rel="noopener">food insecurity</a>. Children in reception year, for example, are <a href="https://digital.nhs.uk/data-and-information/publications/statistical/national-child-measurement-programme/2023-24-school-year" target="_blank" rel="noopener">twice as likely</a> to be obese if they live in the most deprived areas of the UK, compared with those living in more affluent areas. Are we really going to wait for children to become old enough to be prescribed these drugs to “finally defeat” their obesity? Isn’t it better to try and create an environment which means that people who are already worse off don’t carry the excess risks from obesity as well?</p>
<p>To be fair to Streeting, he did also talk about free school meals; but on a public policy basis, the risk is that politicians develop an overreliance on these drugs, handing over the obesity problem to clinics and pharma, while neglecting the need to deal with the socio-political causes in the first place.</p>
<p>Although effective, these drugs are not a panacea; many <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11786232/" target="_blank" rel="noopener">stop using</a> them due to gastric side effects. After stopping, <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9542252/" target="_blank" rel="noopener">most people</a> regain two-thirds of the weight they lost, meaning that some will likely elect to keep taking them in the long term, or end up in a yo-yo pattern. Naturally, for a relatively new drug, we don’t yet have data about <a href="https://pubmed.ncbi.nlm.nih.gov/39171569/" target="_blank" rel="noopener">very long-term</a> side effects. None of this is to diminish the fact that these drugs work, and reduce many of the risks of obesity. But they are not a simple solution that can replace true prevention.</p>
<p>That would mean disrupting the somewhat symbiotic relationship between the drug industry (weight loss) and the food industry (weight gain). In post-Brexit Britain, it’s clear the pharmaceutical industry is seen as key to future economic health. But an effective obesity prevention strategy would aim to reduce the need for weight loss drugs over the coming decades. Let’s hope this particular battleground prioritizes prevention, not just prescriptions.</p>
<style>
				a.appcomments {
					background: #FFF;
					border: 1px solid #446c76 !important;
					font-family: benton-sans,sans-serif;
					font-weight: 600;
					font-style: normal;
					font-size: 12px;
					color: #446c76 !important;
					padding: 12px 50px;
					text-transform: uppercase;
					letter-spacing: 1.5px;
					text-decoration: none;
					width: 100%;
					display: block;
					text-align: center !important;
				 }
			</style>
			<a href="https://stage.unherd.com/newsroom/britain-needs-more-than-ozempic-to-defeat-obesity/?edition=us?appcomments" class="appcomments">view comments</a>]]>
							</content:encoded>
																<unherd:comments_embed_url>https://stage.unherd.com/newsroom/britain-needs-more-than-ozempic-to-defeat-obesity/?edition=us?appcommentsnew</unherd:comments_embed_url>
											<wfw:commentRss>https://stage.unherd.com/newsroom/britain-needs-more-than-ozempic-to-defeat-obesity/?edition=us/feed/</wfw:commentRss>
															<post-id xmlns="com-wordpress:feed-additions:1">1031173</post-id>				</item>
									<item>
					<title>The false hope of the new Alzheimer’s drugs</title>
					<link>https://stage.unherd.com/2025/06/the-false-hope-of-the-new-alzheimers-drugs/?edition=us</link>
											<comments>https://stage.unherd.com/2025/06/the-false-hope-of-the-new-alzheimers-drugs/?edition=us#comments</comments>
										<unherd:featured_image>https://stage.unherd.com/wp-content/uploads/2024/01/GettyImages-535273408-1.jpg?w=537</unherd:featured_image>
										<unherd:main_theme>From The Archive</unherd:main_theme>
					<dc:creator>
						<![CDATA[Margaret McCartney]]>
					</dc:creator>
					<unherd:creator_img>https://stage.unherd.com/wp-content/uploads/2024/02/blued-margaret-300x300-1.jpg?w=96</unherd:creator_img>
																<unherd:article_ranking>International</unherd:article_ranking>
																<unherd:image_caption>
							<![CDATA[(Credit: Ryan Pyle/Corbis via Getty)]]>
						</unherd:image_caption>
						<unherd:twitter_bio>
							<![CDATA[<p><strong>Deborah Cohen</strong> is an award-winning, medically qualified TV, print and radio reporter.</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
]]>
						</unherd:twitter_bio>
						<unherd:twitter_handle>deb_cohen</unherd:twitter_handle>
															<unherd:author_bio>
						<![CDATA[ is a GP and broadcaster.]]>
					</unherd:author_bio>
										<pubDate>Wed, 24 Jan 2024 00:00:00 +0000</pubDate>
					<updated>Thu, 19 Jun 2025 11:13:49 +0000</updated>
							<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[Alzheimer’s]]></category>
		<category><![CDATA[Don't miss]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Science]]></category>
		<category><![CDATA[state of the union]]></category>
		<category><![CDATA[UK]]></category>
					<guid isPermaLink="false">https://old.unherd.com/?p=496982</guid>
																												<description>
								<![CDATA[The NHS was right to reject them ]]>
							</description>
																		
																			<content:encoded>
								<![CDATA[<p>“Dementia steals people’s lives, turns their relationships upside down, destroys their hopes and dreams,” said David Cameron, as president of Alzheimer’s UK. This was back in 2017, and his ambitions were impressive: the Government had just published plans for £60 million research funding a year to bring together industry, charities and academia to “accelerate progress towards disease modifying therapy, and ultimately a cure by 2025”.</p>
<p>So, how likely is that? Are we <em>really </em>on track to be one year away from a cure? Right now, dementia and Alzheimer’s disease are the leading cause of death in England and Wales, with the number of cases predicted to triple over the next 40 years. That means, if nothing changes, one in two of us will be directly affected by it — either by caring for someone with the condition, or developing it ourselves. Yet no new drug has been approved for Alzheimer’s in 20 years.</p>
<p>No wonder, then, that at the end of last year, <a href="https://www.theguardian.com/society/2023/dec/17/new-alzheimers-drugs-bring-hope-of-slowing-disease-for-uk-patients" target="_blank" rel="noopener">the news that two new dementia drugs were set to be approved for use in Britain</a> was greeted with great excitement. The drugs, lecanemab and donanemab, were both celebrated as a “new era” in Alzheimer’s treatment, claiming to slow the progression of disease. Until now, treatment has only slightly alleviated the symptoms, at best. Since the announcement, Alzheimer’s Research UK and the Alzheimer&#8217;s Society have renewed efforts to get them to patients.</p>
<p><span style="font-weight: 400;">Now, we are told that <a href="https://www.thetimes.co.uk/article/alzheimers-blood-test-screening-study-hh8krnz8v" target="_blank" rel="noopener">&#8220;routine screening for over-50s [is] closer&#8221;.</a> Research published this week in <a href="https://jamanetwork.com/journals/jamaneurology/fullarticle/2813751" target="_blank" rel="noopener"><em>JAMA</em> Neurology</a> linked blood test results of a protein implicated in Alzheimer&#8217;s disease, tau, to a later changes on scans. The clamour for the “wonder drugs” will inevitably grow louder. But can we believe the hype?</span></p>
<p>Dementia has long existed across human history. And Alzheimer’s is the most common form. While advances in medicine have increased our understanding of the disease, and we know that age, genetics and lifestyle play a part in the progression of it, we still don’t know what triggers it. Aluminium exposure is one theory; <a href="https://docs.google.com/document/d/13SF7EU3Y5Cv1t0HGERhjJqXXa689Ezlo0nME-_t3Hcs/edit" target="_blank" rel="noopener">infection and immune system malfunctions </a>have also been posited, though are treated as unproven. But the most enduring one, and the one into which most funding flows, is the “Amyloid Hypothesis”.</p>
<p>Amyloid protein is found in all healthy people but in Alzheimer&#8217;s disease, the protein is found to have behaved abnormally: it clumps together forming plaques which cause “tangles” which disrupt communication between the brain cells. The cells malfunction, die and, over time, different areas of the brain shrink.<span style="font-weight: 400;"> The &#8220;clumps&#8221; cause the production of another protein, tau, which causes tangles and more damage; the two have been called the &#8220;trigger and bullet&#8221; in the disease. </span></p>
<p>The two new “wonder drugs” both address the amyloid theory. Both are “monoclonal antibodies”, which target the protein in different ways. Donanemab’s antibodies recognise and remove amyloid when it is in plaque form, while lecanemab targets the amyloid as it forms fibres and tangles. But they don&#8217;t come cheap. Lecanemab is priced at £21,000 per patient annually with donanemab expected to be similar. And this, along with their efficacy, will be what Nice is looking at before it decides to recommend the drug — or not — later this year.</p>
<p>The new drugs certainly seem credible. Large trials have been conducted and published in high-profile journals, examining their impact on memory, brain scans and blood test results.</p>
<div class="ref-ar"><a href="https://stage.unherd.com/2023/01/the-dignity-of-dying-at-home/?edition=us&#038;ref=refinnar" class="text-decoration-none border-0"><a href="https://stage.unherd.com/2023/01/the-dignity-of-dying-at-home/?edition=us&#038;ref=refinnar" class="text-decoration-none border-0"><img decoding="async" src="https://stage.unherd.com/wp-content/uploads/2023/01/Elderly-2-e1674753658461.jpg?w=300" /></a><div class="content"><a href="https://stage.unherd.com/2023/01/the-dignity-of-dying-at-home/?edition=us&#038;ref=refinnar" class="text-decoration-none border-0"><span class="meta">Suggested reading </span></a><a href="https://stage.unherd.com/2023/01/the-dignity-of-dying-at-home/?edition=us&#038;ref=refinnar" class="text-decoration-none border-0"><h5>The dignity of dying at home</h5></a><p class="author"><a href="https://stage.unherd.com/2023/01/the-dignity-of-dying-at-home/?edition=us&#038;ref=refinnar" class="text-decoration-none border-0"><span>By</span> Kate Clanchy</a></p></div></a></div>
<p>The Trailblazer study investigating donanemab was published in <em>JAMA</em> last year. It assessed over 1,700 adults, with an average age of 73, who had been diagnosed with early Alzheimer’s. Over 18 months, half of those studied received the active drug and half the placebo, all of them completing disease scores, indicating symptoms and cognitive ability as the trial progressed.</p>
<p>Eli Lilly, the drug developer, stated in a press release that “47% of participants on donanemab showed no decline on CDR-SB, a key measure of disease severity after 1 year, compared with 29% of participants on placebo.&#8221;  Moreover, “participants on donanemab had 40% less decline in ability to perform activities of daily living at 18 months”. Meanwhile, images of brain scans which seem to persuasively illustrate the disappearance of amyloid were widely published.</p>
<p>Given that dementia progresses over a period of time at differing speeds, the developers were keen to highlight their “rate of decline” measurement. The implication of their results was a significant slowing of the disease. But that by no means tells the whole story. Participants in the trial also had their cognitive function measured on the <a href="https://jamanetwork.com/journals/jama/article-abstract/2807533" target="_blank" rel="noopener">Alzheimer Disease Rating Scale</a>. For those taking the placebo, their scores dropped by an average of 13 points. For those taking donanemab, <a href="https://jamanetwork.com/journals/jama/article-abstract/2807533" target="_blank" rel="noopener">their scores also dropped</a> — but by an average of 10 points. So both groups found their cognitive function worsened, but with a difference of three points on a scale of 146. The question to ask must surely be: how much difference do those three points make.</p>
<p>As for the lecanemab trials, Biogen and Eisai <a href="https://jamanetwork.com/journals/jama/article-abstract/2807533" target="_blank" rel="noopener">announced</a> “highly statistically significant results… representing a 27% slowing of decline”. These were conducted in a slightly different fashion. The 1,795 adults, ranging in age from 50-90, were assessed on an<a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2212948" target="_blank" rel="noopener"> 18-point score</a> in tests which looked at their memory, problem solving, hobbies and abilities in personal care. Half got the active drug, the other half, placebo.</p>
<p>After 18 months, both groups had experienced decline, as would be expected in people with dementia. Those taking lecanemab had scores which had declined by an average of 1.21 points. And those on the placebo had deteriorated more, by an average of 1.66 points over the course of the trial. That&#8217;s a difference of 0.45 points on an 18-point scale, described as “moderate” in the paper.</p>
<p>It is also important to note that the people who were recruited to the trials were only those with the “purest” forms of Alzheimer’s. For every 10 patients put forward, seven or eight were rejected. Those who were accepted had high amyloid levels but were relatively young and free of other diseases. To pick these patients, according to Dr Seb Walsh, a public-health doctor researching dementia at Cambridge University, is to misrepresent how the disease occurs among the vast majority of the population. Most people’s dementia is complex, occurring when they are in their eighties, and caused by several disease processes.</p>
<p>“By selecting amyloid-only patients,” he says, “they were giving the drug the best possible chance to show an effect, and yet even so they found an effect (after 18 months of fortnightly infusion treatment) that was so small it probably wouldn’t be noticeable to a doctor.” If the drug were given to a broader range of people diagnosed with Alzheimer’s disease, the already-small improvements might even disappear altogether.</p>
<p>And there’s another problem. The side effects.</p>
<p>Over a quarter of the participants in the lecanemab trial suffered drug infusion reactions, while there was brain swelling (which can be mild, such as flushing, or more severe, with changes in breathing and heart rate) in 13%. Others experienced headache, confusion and visual disturbance. Donanemab had similar side effects and <a href="https://www.nia.nih.gov/news/nia-statement-donanemab-results-more-alzheimers-research-progress" target="_blank" rel="noopener">three people also died in the trial</a> — something researchers ascribed to the treatment.</p>
<p>So, while the press releases make a persuasive case for the effectiveness of the drugs, the overall difference is so small as to invite the question as to whether patients or families would even notice. What sort of improvement would these small differences represent in the real-world? And more important: are they worth the risk?</p>
<p>“My view,” says Professor Robert Howard, Professor of Old Age Psychiatry at University College London, “is that we&#8217;ve just about reached the point where we couldn&#8217;t have treatments that remove amyloid more aggressively because of the side effects of brain bleeds and swelling.”</p>
<p>It is this finding that is exercising — and dividing — scientists. For what does it mean for the new drugs if, as the trial showed, a big reduction in brain amyloid doesn’t translate into a hugely impressive reduction in or slowing down of symptoms.</p>
<p>One body of clinicians continues to hold to the hypothesis. Craig Ritchie, a Professor of the Psychiatry of Aging at the University of Edinburgh, <a href="https://pubmed.ncbi.nlm.nih.gov/37459141/" target="_blank" rel="noopener">worked on the donanemab trial</a> and claims it has “a profound effect on the core pathology of Alzheimer’s disease namely cerebral amyloid”. He maintains that the slowing of the progression of the disease coupled with a reduction in amyloid build-up is not a coincidence. He believes that more time is needed to show the full impact of the reduction in amyloid on symptoms. “These drugs give us hope that we can do something, that these are the first drugs of an important new generation of treatments.” In order to push out this treatment, he has quit the NHS and set up Scottish Brain Sciences as an “independent research company” to run studies and give patients free access to the latest diagnostic tests and medications through trials funded by the drug industry. He, too, is funded by the industry.</p>
<p>These proponents of the new drugs also insist that monoclonal antibodies will show more impact if they are given before amyloid has damage to the brain. Therefore, they say, it needs to be given earlier — possibly even before someone has any symptoms of dementia.</p>
<p><span style="font-weight: 400;">That’s where the proposal that screening people — the so-called &#8220;Alzheimer’s blood test&#8221;  would come in. It would test people before they have any memory problems for their future dementia risk. But, offered as a &#8220;check up&#8221;, it would come with wide ethical issues. There would inevitably be false positives and negatives — causing needless anxiety or false reassurance. Nor would a result necessarily lead to people being offered treatments that could lower their chances of getting dementia later. But could it make sense in a research setting, as an opportunity to try these new treatments to see if they could make a difference if given earlier? </span></p>
<p><span style="font-weight: 400;">Professor Howard is sceptical. The amyloid treatment, he says, “is a cul de sac, a dead end. And, worse, it means that the money and energy in drug development and trials isn&#8217;t being put into something that might work.” he says. “The argument that maybe the drugs need to be given earlier to make a difference is really just a wish or a hope. There is no data to suggest that it is true,” he says. “I worry that the “treat earlier” argument has become a way of saying ‘don’t blame the drugs for not working, blame the patients’.”</span></p>
<div class="ref-ar"><a href="https://stage.unherd.com/2023/08/the-cruelty-of-canadas-euthanasia-policy-maid/?edition=us&#038;ref=refinnar" class="text-decoration-none border-0"><a href="https://stage.unherd.com/2023/08/the-cruelty-of-canadas-euthanasia-policy-maid/?edition=us&#038;ref=refinnar" class="text-decoration-none border-0"><img decoding="async" src="https://stage.unherd.com/wp-content/uploads/2023/08/gergerrgr-1.jpeg?w=300" /></a><div class="content"><a href="https://stage.unherd.com/2023/08/the-cruelty-of-canadas-euthanasia-policy-maid/?edition=us&#038;ref=refinnar" class="text-decoration-none border-0"><span class="meta">Suggested reading </span></a><a href="https://stage.unherd.com/2023/08/the-cruelty-of-canadas-euthanasia-policy-maid/?edition=us&#038;ref=refinnar" class="text-decoration-none border-0"><h5>The cruelty of Canada&#039;s euthanasia policy</h5></a><p class="author"><a href="https://stage.unherd.com/2023/08/the-cruelty-of-canadas-euthanasia-policy-maid/?edition=us&#038;ref=refinnar" class="text-decoration-none border-0"><span>By</span> Lionel Shriver</a></p></div></a></div>
<p>Various Alzheimer’s charities have heavily advocated for these drugs to be made available quickly. When lecanemab was approved in the US, a public letter hosted by the US Alzheimer&#8217;s Association in 2023 described it as “a foundational gamechanger”, saying: “No barrier can be allowed to stand between our patients and a treatment that has a reasonable risk-benefit ratio.” There may be a less philanthropic reason why they are so enthusiastic about the new treatments. A closer look at the signatories revealed that some had drug industry connections. And the charity itself received over $750,000 from Eisai and $430,000 from Biogen in 2023, who make lecanemab.</p>
<p>The inevitable result of these two amyloid-removing drugs being licensed means all drug companies will want to make and market their own versions, regardless of the criticisms. After all, it’s harder for regulators to say “no” when there are similar drugs on the market and the big charities are rooting for them.</p>
<p>But that hasn’t stopped the charities from investing £5 million in developing a blood test that will “revolutionise dementia diagnosis”. They say that currently only 2% of people get the detailed diagnosis they need and that significant investment is needed to ensure the NHS can identify people with Alzheimer’s disease far sooner. The Blood Biomarker Challenge, available within five years, will help do that. “If we can fix diagnosis, we open the door for a cure. It’s a bold ambition but, with someone developing dementia every three minutes in the UK, we must aim high,” they say.</p>
<p>But Dr Seb Walsh, a public health doctor researching dementia at the University of Cambridge, says the hype and hope is unkind: “For 20 years we have been promised wonder drugs within 5 years — but still we wait,” he says.</p>
<p>He also says it’s bad research practice to pre-empt your results before you do the research. “We don’t know how useful these tests will be, how well they’ll perform in the ‘typical’ NHS dementia patient (more complex than the people in existing research studies), that’s the whole point of doing the research.”</p>
<p>But the key question, and the one that Nice will be weighing up over the course of the year, is whether any of these new drugs represent the best use of public money. Given the small benefits, the risk of side effects, but the lack of other decent alternatives, the question will be how to weigh that up as independently as possible. Spending similar sums on social care might well provide greater benefits for patients and families than the drugs. Is it right that a drug — with minimal benefits — should be funded when the same money invested into social care might do more good for patients and families getting more practical help?</p>
<p>Obviously, a drug that worked would have massive, global market potential. But the hyperbole from doctors and researchers in this area — especially those with industry funding — is unhelpful. It means that the pressure to upsell the effectiveness of a drug is particularly intense. This, then, diverts money into look-alike drug development and drains it from continued research. Clearly the pharmaceutical industry and its relationship with the private and public sectors has a lot to answer for. Currently, Alzheimer’s has no cure and treatment has progressed little despite decades of research and billions of pounds. As our investigation shows, we should be cautious about the promise of these new “wonder” drugs which risk benefiting only the drugs companies.</p>
<p>“There is still much we don’t know, but we really need to know,” Dr Walsh says. “We are unlikely to ever, truly ‘cure’ dementia — this is more false hope.”</p>
<style>
				a.appcomments {
					background: #FFF;
					border: 1px solid #446c76 !important;
					font-family: benton-sans,sans-serif;
					font-weight: 600;
					font-style: normal;
					font-size: 12px;
					color: #446c76 !important;
					padding: 12px 50px;
					text-transform: uppercase;
					letter-spacing: 1.5px;
					text-decoration: none;
					width: 100%;
					display: block;
					text-align: center !important;
				 }
			</style>
			<a href="https://stage.unherd.com/2025/06/the-false-hope-of-the-new-alzheimers-drugs/?edition=us?appcomments" class="appcomments">view comments</a>]]>
							</content:encoded>
																<unherd:comments_embed_url>https://stage.unherd.com/2025/06/the-false-hope-of-the-new-alzheimers-drugs/?edition=us?appcommentsnew</unherd:comments_embed_url>
											<wfw:commentRss>https://stage.unherd.com/2025/06/the-false-hope-of-the-new-alzheimers-drugs/?edition=us/feed/</wfw:commentRss>
															<post-id xmlns="com-wordpress:feed-additions:1">488843</post-id>				</item>
									<item>
					<title>Has Zoe Ball fallen victim to a pseudoscientific TMJ treatment?</title>
					<link>https://stage.unherd.com/newsroom/has-zoe-ball-fallen-victim-to-a-pseudoscientific-tmj-treatment/?edition=us</link>
											<comments>https://stage.unherd.com/newsroom/has-zoe-ball-fallen-victim-to-a-pseudoscientific-tmj-treatment/?edition=us#comments</comments>
										<unherd:featured_image>https://stage.unherd.com/wp-content/uploads/2024/12/Screenshot-2024-12-01-at-11.26.32.png?w=626</unherd:featured_image>
										<unherd:main_theme></unherd:main_theme>
					<dc:creator>
						<![CDATA[Margaret McCartney]]>
					</dc:creator>
					<unherd:creator_img>https://stage.unherd.com/wp-content/uploads/2024/02/blued-margaret-300x300-1.jpg?w=96</unherd:creator_img>
																									<unherd:author_bio>
						<![CDATA[ is a GP and broadcaster.]]>
					</unherd:author_bio>
										<pubDate>Sun, 01 Dec 2024 19:00:24 +0000</pubDate>
					<updated>Sun, 01 Dec 2024 22:03:40 +0000</updated>
							<category><![CDATA[lymphodema]]></category>
		<category><![CDATA[modern medicine]]></category>
		<category><![CDATA[none]]></category>
		<category><![CDATA[pseudoscience]]></category>
		<category><![CDATA[Science]]></category>
		<category><![CDATA[TMJ]]></category>
					<guid isPermaLink="false">https://stage.unherd.com/?post_type=newsroom&#038;p=641373</guid>
																												<description>
								<![CDATA[The BBC host claimed that a lymphatic drainage massage improved her condition]]>
							</description>
																		
																			<content:encoded>
								<![CDATA[<p>I have long harboured a dream to visit an evidence-based spa. I very much enjoy sybaritic relaxation, but the infrequency of my spa-visiting is directly related to the rage induced when claims for the effectiveness of various administered “therapies” are made, usually when in a prone and near naked state. I like massages, scented oils, warm towels and luxuriance, but I do not like pseudoscience and fake claims — and I definitely don’t want to be wasting money on it.</p>
<p>Radio DJ Zoe Ball has resigned from her Radio 2 show after writing that she has been having <a href="https://www.bbc.com/news/articles/c9wr95njpzpo" target="_blank" rel="noopener">significant problems</a> with her TMJ — the temporomandibular joint, which connects the jaw to the skull. Pain from the joint is relatively common and can be very unpleasant, leading to headaches and often painful chewing. The condition is sometimes connected to anxiety and stress. She has reportedly visited a clinic that offers “lymphatic drainage massage” and thanked them for helping her. The clinic also provides “cup therapy”, which is in vogue, with famous people on red carpets revealing the circular marks on their flesh that result from it — vacuum suction is applied to skin via “cups” with the intention of removing “toxins&#8221;.</p>
<p>People should be able to spend their money how they want, and many people find massage soothing and a good distraction from pain. But look online, and you will find vast claims made by multiple vendors — and that is my issue. While some people can afford, and be willing, to pay for things that offer a short-lived placebo effect, it would be fairer to explain that is, in fact, what they are purchasing. (And there is some evidence that beneficial placebo effects can still be generated even when the person is <a href="https://www.nature.com/articles/s41598-021-83148-6" target="_blank" rel="noopener">told they are being given</a> a placebo. In other words, it’s possible to be transparent and still feel a bit better). Many clinics offer lymphatic drainage massage — which sounds science-y — and indeed the lymph system is one of the most under-appreciated parts of our anatomy, continually and quietly protecting us from infections.</p>
<p>However it is touted on multiple beauty therapy websites as a means to “reduce the signs of ageing”, again via a release of “toxins”. (The lymphatic system will carry on doing that for us, regardless). A variety of hand-held implements, including rollers made of jade, are available for doing the “lymphatic massage” job if one does not wish to visit a therapist. (This is quite different from the physical treatments for lymphodema, a condition where the lymphatic system is blocked, resulting in limb swelling, which can be a consequence of some types of cancer surgery.) And again, there is a distinct lack of evidence that this can help pain.</p>
<p>But it is also true that neither does traditional medicine have great answers, although <a href="https://pubmed.ncbi.nlm.nih.gov/37373852/" target="_blank" rel="noopener">physiotherapy can help</a>. There are some ways to mitigate the pain, such as “occlusal splints” — a mouthguard usually worn at night — but the <a href="https://www.cochrane.org/CD012850/ORAL_what-are-benefits-and-risks-occlusal-treatment-people-temporomandibular-jaw-joint-disorders" target="_blank" rel="noopener">evidence quality</a> on them is poor. Meantime, a self-management programme, designed to help people control their physical and mental response to pain does <a href="https://eprints.whiterose.ac.uk/175711/47/Implementation%20of%20Biopsychosocial%20Supported-Self-Management%20for%20Chronic%20Primary%20Orofacial%20Pain.pdf" target="_blank" rel="noopener">seem to have an impact</a>. But it is far better to be honest about the limitations of what&#8217;s on offer. First, interventions that can&#8217;t help you can only harm you (either financially or by side effects) and second, if we keep doing the same thing that doesn&#8217;t work, then we will never get any better treatments for anyone.</p>
<p>So what’s the problem, then, if people take an alternative path? If a placebo effect works, or people get temporary relief from pain, isn&#8217;t that a good thing? Yes and no. I want the same standards for all — whether it&#8217;s conventional medicine or labelled “alternative&#8221; (and as Richard Dawkins once said, &#8220;when alternative treatments are shown to work, they are no longer called alternative medicine, just medicine&#8221;). People with chronic pain are often suffering badly. If we are sold treatments without decent evidence of benefit and with promises beyond what can be achieved, we are potentially exploiting people, whether it’s labelled “alternative” or not.</p>
<p>Truth be told, I dream of a spa where I am told, not that toxins will be removed and energy fields will be rebalanced, but that this should smell nice, feel nice, and just relax and enjoy it.</p>
<style>
				a.appcomments {
					background: #FFF;
					border: 1px solid #446c76 !important;
					font-family: benton-sans,sans-serif;
					font-weight: 600;
					font-style: normal;
					font-size: 12px;
					color: #446c76 !important;
					padding: 12px 50px;
					text-transform: uppercase;
					letter-spacing: 1.5px;
					text-decoration: none;
					width: 100%;
					display: block;
					text-align: center !important;
				 }
			</style>
			<a href="https://stage.unherd.com/newsroom/has-zoe-ball-fallen-victim-to-a-pseudoscientific-tmj-treatment/?edition=us?appcomments" class="appcomments">view comments</a>]]>
							</content:encoded>
																<unherd:comments_embed_url>https://stage.unherd.com/newsroom/has-zoe-ball-fallen-victim-to-a-pseudoscientific-tmj-treatment/?edition=us?appcommentsnew</unherd:comments_embed_url>
											<wfw:commentRss>https://stage.unherd.com/newsroom/has-zoe-ball-fallen-victim-to-a-pseudoscientific-tmj-treatment/?edition=us/feed/</wfw:commentRss>
															<post-id xmlns="com-wordpress:feed-additions:1">641373</post-id>				</item>
									<item>
					<title>Why are food allergies rising among children?</title>
					<link>https://stage.unherd.com/newsroom/why-are-food-allergies-rising-among-children/?edition=us</link>
											<comments>https://stage.unherd.com/newsroom/why-are-food-allergies-rising-among-children/?edition=us#comments</comments>
										<unherd:featured_image>https://stage.unherd.com/wp-content/uploads/2024/09/Screenshot-2024-09-01-at-11.25.08.jpeg?w=537</unherd:featured_image>
										<unherd:main_theme></unherd:main_theme>
					<dc:creator>
						<![CDATA[Margaret McCartney]]>
					</dc:creator>
					<unherd:creator_img>https://stage.unherd.com/wp-content/uploads/2024/02/blued-margaret-300x300-1.jpg?w=96</unherd:creator_img>
																									<unherd:author_bio>
						<![CDATA[ is a GP and broadcaster.]]>
					</unherd:author_bio>
										<pubDate>Sun, 01 Sep 2024 15:00:41 +0000</pubDate>
					<updated>Sun, 01 Sep 2024 15:07:47 +0000</updated>
							<category><![CDATA[Non classifié(e)]]></category>
		<category><![CDATA[allergies]]></category>
		<category><![CDATA[Children]]></category>
		<category><![CDATA[NHS]]></category>
		<category><![CDATA[none]]></category>
		<category><![CDATA[peanuts]]></category>
		<category><![CDATA[Science]]></category>
					<guid isPermaLink="false">https://stage.unherd.com/?post_type=newsroom&#038;p=619188</guid>
																												<description>
								<![CDATA[]]>
							</description>
																		
																			<content:encoded>
								<![CDATA[<p>Two decades ago, the advice to a newly-minted mother like me was: don’t give your child peanuts. Not just giving whole ones to infants where they’d be a choking risk — but peanuts at all, as butter or an ingredient, lest they develop an allergy.</p>
<p>Peanut allergies, at their most serious, can be life-threatening. They are one of the main causes of anaphylaxis, which causes lip and tongue swelling, and circulatory collapse, with a dramatic fall in blood pressure and difficulty breathing. People who know they have these types of reactions will be recommended to carry emergency doses of adrenaline, designed to be injected quickly and abort the reaction.</p>
<p>Deaths are mercifully rare — around <a href="https://www.allergyuk.org/mp-toolkit/statistics/" target="_blank" rel="noopener">10 people die per year</a> from food allergies in the UK — but <a href="https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(24)00163-4/fulltext" target="_blank" rel="noopener">a new study from Imperial College London</a> signals that allergies are now relatively common. The researchers searched millions of GP records for signs that allergy was an issue for patients, and found an increase in reports from 0.4% of patients in 2008 to 1.1% in 2018. In 2018, the highest reports were in children under 5, of whom 4% had food allergies. The researchers say this rise has likely reached a plateau, but why did it occur in the first place?</p>
<p>Various theories have been advanced over the years. The “hygiene hypothesis” suggests that early exposure to bugs creates a protective natural immunity, which in turn reduces the risk of allergies. However, the data on which this is based is mainly observational, where people moving from low-allergy countries to high-allergy countries <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2841828/" target="_blank" rel="noopener">develop the risk</a> of the place they are living in.</p>
<p>Another <a href="https://pubmed.ncbi.nlm.nih.gov/19000582/" target="_blank" rel="noopener">piece of research</a> highlighted how Jewish children brought up in the UK had 10 times the risk of peanut allergy compared with Jewish children brought up in Israel — where peanuts are routinely in children’s diets before the age of 1. This is clearly interesting but didn’t prove cause and effect, which is why a <a href="https://www.leapstudy.co.uk/index.html" target="_blank" rel="noopener">series of studies</a> done in the UK a decade ago are crucial to understand what might be happening.</p>
<p>These studies took the presumption that avoiding peanuts to avoid allergy was sensible and turned it on its head. Instead they asked whether this avoidance might actually be making things worse. So they carried out a series of randomised controlled trials — a powerful way to try and untangle cause and effect. Noting that when they did the study, peanut allergy had doubled in Western countries over the previous decade, they took 640 infants who had severe eczema or egg allergy, and who would have been at high risk to develop a peanut allergy as well. They split the children into two groups, with one group told to continue to avoid peanuts and the other recommended to eat them.</p>
<p>They were followed up, and 60 months later it was clear that there was a marked difference between the groups. Almost 14% of children avoiding peanuts had a reaction to them on a skin-prick sensitivity test compared to just under 2% of the children who ate them. In other words, the peanut exposure had a protective effect; worldwide, guidelines telling parents about what to feed their children were updated. Now, the NHS <a href="https://www.nhs.uk/conditions/baby/weaning-and-feeding/food-allergies-in-babies-and-young-children/" target="_blank" rel="noopener">recommends</a> that peanuts can be given, ground or as a paste, from six months old.</p>
<p>There are several lessons contained within this policy turnaround. First, where we don’t know what the best advice is, we should admit that uncertainty. It’s easy to assume that what sounds sensible actually is. It might be — but it also might not. The second is admitting that uncertainty enables us to do fair tests of interventions. This in turn can give people accurate advice and enable them to avoid harms. We can’t tell for sure from this data, but the change in policy might be arresting the previously observed rises in peanut allergy.</p>
<p>The third is that high-quality trials are a broader social good. The children who took part in the peanut trials had a good chance of getting the most effective advice rather than the (wrong) advice being given at the time — even though they didn’t know it yet. We should be profoundly grateful to researchers willing to question the status quo: it’s what better healthcare depends on.</p>
<style>
				a.appcomments {
					background: #FFF;
					border: 1px solid #446c76 !important;
					font-family: benton-sans,sans-serif;
					font-weight: 600;
					font-style: normal;
					font-size: 12px;
					color: #446c76 !important;
					padding: 12px 50px;
					text-transform: uppercase;
					letter-spacing: 1.5px;
					text-decoration: none;
					width: 100%;
					display: block;
					text-align: center !important;
				 }
			</style>
			<a href="https://stage.unherd.com/newsroom/why-are-food-allergies-rising-among-children/?edition=us?appcomments" class="appcomments">view comments</a>]]>
							</content:encoded>
																<unherd:comments_embed_url>https://stage.unherd.com/newsroom/why-are-food-allergies-rising-among-children/?edition=us?appcommentsnew</unherd:comments_embed_url>
											<wfw:commentRss>https://stage.unherd.com/newsroom/why-are-food-allergies-rising-among-children/?edition=us/feed/</wfw:commentRss>
															<post-id xmlns="com-wordpress:feed-additions:1">619188</post-id>				</item>
									<item>
					<title>We need to talk about ZOE</title>
					<link>https://stage.unherd.com/2023/10/we-need-to-talk-about-zoe/?edition=us</link>
											<comments>https://stage.unherd.com/2023/10/we-need-to-talk-about-zoe/?edition=us#comments</comments>
										<unherd:featured_image>https://stage.unherd.com/wp-content/uploads/2023/10/2023-10-10-unherd-zoe-patch-pub.jpg?w=747</unherd:featured_image>
										<unherd:main_theme> </unherd:main_theme>
					<dc:creator>
						<![CDATA[Margaret McCartney]]>
					</dc:creator>
					<unherd:creator_img>https://stage.unherd.com/wp-content/uploads/2024/02/blued-margaret-300x300-1.jpg?w=96</unherd:creator_img>
																<unherd:article_ranking>1</unherd:article_ranking>
																<unherd:image_caption>
							<![CDATA[]]>
						</unherd:image_caption>
						<unherd:twitter_bio>
							<![CDATA[<p><strong>Deborah Cohen</strong> is an award-winning, medically qualified TV, print and radio reporter.</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
]]>
						</unherd:twitter_bio>
						<unherd:twitter_handle>deb_cohen</unherd:twitter_handle>
															<unherd:author_bio>
						<![CDATA[ is a GP and broadcaster.]]>
					</unherd:author_bio>
										<pubDate>Wed, 11 Oct 2023 23:03:08 +0000</pubDate>
					<updated>Wed, 22 May 2024 13:53:49 +0000</updated>
							<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[Diabetes]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Influencers]]></category>
		<category><![CDATA[none]]></category>
		<category><![CDATA[Premium]]></category>
		<category><![CDATA[Science]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Tim Spector]]></category>
		<category><![CDATA[ZOE]]></category>
					<guid isPermaLink="false">https://old.unherd.com/?p=487752</guid>
																												<description>
								<![CDATA[How scientific is the must-have health app?]]>
							</description>
																		
																			<content:encoded>
								<![CDATA[<p><b>Professor Tim Spector was one of the &#8220;winners&#8221; of the Covid era: his ZOE symptom tracker app accrued millions of users during the pandemic. </b></p>
<p><b>Now he has pivoted back to his true passion, gut health, and taken many of his followers with him. Endorsed by celebrities such as Davina McCall and Carrie Johnson, the new version of the ZOE app promises a personalised nutrition plan and comes with a glucose blood monitor usually used by diabetics. It is proving hugely popular, with over 100,000 subscribers paying up to £600 in their first year — and a further 300,000 on the waiting list. </b><br />
<a name="continuereading"></a><br />
<b>It boasts all the hallmarks of a scientific endeavour, with endorsements by world-leading experts and numerous studies. But how convincing are its claims?</b></p>
<p><b>Deborah Cohen, a medically qualified TV, print and radio reporter</b><b>, and Margaret McCartney, a GP, undertook a forensic investigation for <em>UnHerd</em> and found that ZOE’s scientific foundations aren’t as strong as they would have you think…</b></p>
<p><b>Read on to learn about:</b></p>
<p><a href="#influencers"><strong>1. ZOE and the influencers</strong></a><br />
<a href="#spector"><strong>2. Why Tim Spector created</strong><strong> ZOE</strong></a><br />
<a href="#healthy"><strong>3. Does ZOE think you are healthy?</strong></a><br />
<a href="#data"><strong>4. Why ZOE wants your data</strong></a><br />
<a href="#gut"><strong>5. What does your gut tell ZOE? </strong></a><br />
<a href="#scientific"><strong>6. How scientific is ZOE? </strong></a></p>
<p>&nbsp;</p>
<p style="text-align: center;"><strong>***</strong></p>
<p><a name="influencers"></a><br />
<strong>1. ZOE and the influencers</strong></p>
<div class="row">
<div class="col-sm-10 offset-sm-1">
<blockquote class="instagram-media" style="background: #FFF; border: 0; border-radius: 3px; box-shadow: 0 0 1px 0 rgba(0,0,0,0.5),0 1px 10px 0 rgba(0,0,0,0.15); margin: 1px; max-width: 658px; min-width: 326px; padding: 0; width: calc(100% - 2px);" data-instgrm-permalink="https://www.instagram.com/p/CwAbROionx0/?utm_source=ig_embed&amp;utm_campaign=loading" data-instgrm-version="14">
<div style="padding: 16px;">
<p>&nbsp;</p>
<div style="display: flex; flex-direction: row; align-items: center;">
<div style="background-color: #f4f4f4; border-radius: 50%; flex-grow: 0; height: 40px; margin-right: 14px; width: 40px;"></div>
<div style="display: flex; flex-direction: column; flex-grow: 1; justify-content: center;">
<div style="background-color: #f4f4f4; border-radius: 4px; flex-grow: 0; height: 14px; margin-bottom: 6px; width: 100px;"></div>
<div style="background-color: #f4f4f4; border-radius: 4px; flex-grow: 0; height: 14px; width: 60px;"></div>
</div>
</div>
<div style="padding: 19% 0;"></div>
<div style="display: block; height: 50px; margin: 0 auto 12px; width: 50px;"></div>
<div style="padding-top: 8px;">
<div style="color: #3897f0; font-family: Arial,sans-serif; font-size: 14px; font-style: normal; font-weight: 550; line-height: 18px;">View this post on Instagram</div>
</div>
<div style="padding: 12.5% 0;"></div>
<div style="display: flex; flex-direction: row; margin-bottom: 14px; align-items: center;">
<div>
<div style="background-color: #f4f4f4; border-radius: 50%; height: 12.5px; width: 12.5px; transform: translateX(0px) translateY(7px);"></div>
<div style="background-color: #f4f4f4; height: 12.5px; transform: rotate(-45deg) translateX(3px) translateY(1px); width: 12.5px; flex-grow: 0; margin-right: 14px; margin-left: 2px;"></div>
<div style="background-color: #f4f4f4; border-radius: 50%; height: 12.5px; width: 12.5px; transform: translateX(9px) translateY(-18px);"></div>
</div>
<div style="margin-left: 8px;">
<div style="background-color: #f4f4f4; border-radius: 50%; flex-grow: 0; height: 20px; width: 20px;"></div>
<div style="width: 0; height: 0; border-top: 2px solid transparent; border-left: 6px solid #f4f4f4; border-bottom: 2px solid transparent; transform: translateX(16px) translateY(-4px) rotate(30deg);"></div>
</div>
<div style="margin-left: auto;">
<div style="width: 0px; border-top: 8px solid #F4F4F4; border-right: 8px solid transparent; transform: translateY(16px);"></div>
<div style="background-color: #f4f4f4; flex-grow: 0; height: 12px; width: 16px; transform: translateY(-4px);"></div>
<div style="width: 0; height: 0; border-top: 8px solid #F4F4F4; border-left: 8px solid transparent; transform: translateY(-4px) translateX(8px);"></div>
</div>
</div>
<div style="display: flex; flex-direction: column; flex-grow: 1; justify-content: center; margin-bottom: 24px;">
<div style="background-color: #f4f4f4; border-radius: 4px; flex-grow: 0; height: 14px; margin-bottom: 6px; width: 224px;"></div>
<div style="background-color: #f4f4f4; border-radius: 4px; flex-grow: 0; height: 14px; width: 144px;"></div>
</div>
<p>&nbsp;</p>
<p style="color: #c9c8cd; font-family: Arial,sans-serif; font-size: 14px; line-height: 17px; margin-bottom: 0; margin-top: 8px; overflow: hidden; padding: 8px 0 7px; text-align: center; text-overflow: ellipsis; white-space: nowrap;"><a style="color: #c9c8cd; font-family: Arial,sans-serif; font-size: 14px; font-style: normal; font-weight: normal; line-height: 17px; text-decoration: none;" href="https://www.instagram.com/p/CwAbROionx0/?utm_source=ig_embed&amp;utm_campaign=loading" target="_blank" rel="noopener">A post shared by Tim Spector MD FRCP OBE (@tim.spector)</a></p>
</div>
</blockquote>
<p><script src="https://www.instagram.com/embed.js" async=""></script></p>
</div>
</div>
<p>“I gave up after a month.” Gail, 49, is talking about her experience of using the ZOE app — the heavily promoted personalised nutrition plan that, we’re told, will help us understand our bodies and make us more healthy. “It certainly didn’t change my food compulsion — if anything, it made me feel worse.”</p>
<p>Take a look at ZOE’s lavish series of adverts, or the rapturous response to the app on social media, and you would be forgiven for thinking that Gail is an anomaly. TikTok, Facebook and Instagram are filled with celebrities, ZOE “members” and influencers sharing their positive experiences and inviting you to join the club.<br />
<a name="continuereading"></a><br />
One is Carrie Johnson, who recently shared her welcome email on Instagram, another is Davina McCall, one of the faces of ZOE’s marketing campaign. She claims she is now “living her best life”, telling prospective consumers (and her 1.7 million Instagram followers) that the knowledge provided by the technology is the “greatest gift ever”. A vocal menopause-awareness campaigner, McCall claims the gut microbiome is “completely different” in pre- and post-menopausal women.</p>
<p>But women only make up part of the market. Steven Bartlett, of <em>Diary of a CEO</em> podcast, is also an ambassador: “There’s an incredible correlation between what I’ve eaten, my blood glucose levels, and how I’m feeling,” he claims.</p>
<p>These three are among the 117,000 people who ZOE claims are now “members”. Another 300,000 are on the waiting list. This, despite the fact that ZOE isn’t cheap: it costs £24.99 per month (roughly £300 per year) and £299.99 for the intro kit which includes the instantly recognisable bright yellow blood glucose monitor that users display proudly.<br />
<a id="“continuereading”"></a><br />
These monitors are all part of a “personalised nutrition” plan that also measures your gut “microbiome”: the collection of “good” and potentially “bad” microorganisms in your intestines. This is assessed via stool samples which you collect in a “hammock” over the loo bowl and then post to the “lab” for testing.</p>
<p>After a fortnight of continuous blood sugar monitoring, combined with your gut bug measurement, you are provided with a nutritional programme — basically foods you should eat and those you should avoid. ZOE suggests that this sort of personalised approach can help with energy levels, reduce hunger, help you reach a healthy weight, feel less bloated, sleep better, and avoid chronic health issues.</p>
<p>But is ZOE the solution? Certainly, its stratospheric rise is a marketing triumph. But beneath the sheen of its glossy adverts and its wealth of medical testimonies, ZOE’s scientific foundations seem far from healthy…</p>
<div><div style="left: 0; width: 100%; height: 0; position: relative; padding-bottom: 56.25%;"><iframe src="//cdn.iframe.ly/api/iframe?url=https%3A%2F%2Fyoutu.be%2F_lmFI-2c2c4&amp;key=357d953055da7177194e1a84a2d8a5a3&amp;playerjs=1" style="border: 0; top: 0; left: 0; width: 100%; height: 100%; position: absolute;" allowfullscreen scrolling="no" allow="encrypted-media; accelerometer; gyroscope; picture-in-picture; autoplay"></iframe></div></div>
&nbsp;
<p><a name="spector"></a><br />
<strong>2. Why Tim Spector created</strong><strong> ZOE</strong></p>
<figure id="attachment_487806" aria-describedby="caption-attachment-487806" style="width: 716px" class="wp-caption alignnone"><img loading="lazy" decoding="async" class=" wp-image-487806" src="https://stage.unherd.com/wp-content/uploads/2023/10/G65TE6-300x200.jpg" alt="" width="716" height="477" /><figcaption id="caption-attachment-487806" class="wp-caption-text">Tim Spector, centre. (Anthony Devlin/Alamy Stock Photo)</figcaption></figure>
<p>From its inception in 2018, ZOE has relied heavily on the profile and academic credentials of co-founder Tim Spector, professor of genetic epidemiology at King’s College London. Already a familiar name in nutrition circles, he rose to prominence during the pandemic with his ZOE Covid symptom tracker app, described by <em>The</em> <em>Financial Times</em> as “arguably the world’s largest ever citizen science experiment”. With millions logging on to share their test results and symptoms, Spector’s app, boosted by £5 million of government funding, was credited with first highlighting that loss of taste and smell accompany Covid infection.</p>
<p>A self-described “measured risk-taker”, Spector told <a href="https://www.ft.com/content/b1b60f54-5d32-4644-a5f9-27af3c1704c7"><em>The FT</em></a> that he moves from subject to subject “if I’m not very interested in the next step or the next stage any more”. He started out as a rheumatologist, treating joint and muscle disorders, before turning to epigenetics, the study of how behaviours and environment can affect the way your genes work. Then, he set up the UK Twins Registry, one of the richest collections of data about identical and non-identical twins in the world.</p>
<p>It was this work, in particular, that led to his current interest: the interplay between diet and gut health. When he was studying the genetics of obesity in twins, he noticed that their weight sometimes greatly varied — which he attributed to the fact that <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5082693/">their gut microbes were different</a>.</p>
<p>After this Eureka moment, he decided to focus his efforts on nutrition, writing several books, the most recent being <em>Food for Life: The New Science of Eating Well </em>(2022). And he takes his own advice seriously — eating plenty of “fermented food” such as kombucha, kefir and kimchi to help his microbiome. He also microdoses on a diabetes drug which, he claims, could have anti-ageing benefits.</p>
<p>According to Spector’s website, it was during one of his presentations on his microbiome research that he met his ZOE co-founders, the now-CEO Jonathan Wolf and president George Hadjigeorgiou, both of whom have backgrounds in machine learning and business. They “shared his vision of helping individuals understand their unique biology to improve their own wellbeing in an accessible way”.</p>
<p>After opening offices in Boston and London, they rapidly attracted $27 million in initial funding to commercialise Spector’s work. (He remains a part-time ZOE employee and company shareholder.) And in 2019, they paid for a study that seemed to confirm the key concept for ZOE’s entry point into a crowded consumer market of products that offer advice on the healthiest foods to eat.</p>
<p>The PREDICT1 study suggested individuals’ metabolic responses to the same foods vary remarkably, with genes only playing a small part. (More on what you can infer from it later.) At a conference in the US, Spector revealed that they had found “really surprising” variation between certain biomarker responses — including some of those used by ZOE — to standardised meals.</p>
<p>It was what other investors needed to hear. The combination of a personalised nutrition app coupled with machine-learning and big data proved to be alluring buzzwords for the wellness-obsessed digital world. Steven Bartlett invested more than £2 million earlier this year. ZOE, he says, is a company that represents “the future”. It is “health science, driven by big data” that doesn’t just extend “our lifespan, but more importantly our health span”. Venture capitalists and those involved in a crowdfunding exercise thought similarly. Last year, one of the CEOs <a href="https://techcrunch.com/2022/12/01/zoe-which-went-viral-with-its-covid-tracking-app-raises-30m-at-a-303m-valuation-to-track-nutrition/">valued</a> the company at over £209 million.</p>
<p>Yet some are sceptical. They suggest this is just the latest iteration of Big Diet — or Big Nutrition. “This is a classic playbook. X doesn’t work; the experts are wrong; read my book and find out the truth. Then buy my product which FINALLY fixes everything,” says one critic, who did not want to be named. Interestingly, Spector himself used to be of these sceptical voices, writing cautiously in <a href="https://www.bmj.com/content/361/bmj.k2179#:~:text=In%20humans%2C%20observational%20studies%20can,in%20particular%2C%20randomised%20controlled%20trials."><em>The British Medical Journal</em></a> in 2018 that observational studies — such as those since published by ZOE —  are limited by the inability to measure causal relations between microbes and health traits. They can only show associations.</p>
<p>“The strongest level of evidence is obtained from interventional clinical studies — in particular, randomised controlled trials,” he wrote. (ZOE is yet to publish controlled trial data.) In 2019, he again suggested evidence was limited. In the same year he promoted ZOE study findings at that US nutrition conference, <span style="font-weight: 400;">Spector </span><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6950569/"><span style="font-weight: 400;">wrote</span></a><span style="font-weight: 400;"> </span><span style="font-weight: 400;">in a medical journal</span><span style="font-weight: 400;">, that “there is a lack of long term human studies, or indeed follow-ups of short-term dietary interventions” to understand whether “diet-induced modulation of the gut microbiota endures”. Could this barrier be overcome?</span></p>
<p><a name="healthy"></a><br />
<strong>3. Does Zoe think you are healthy?</strong></p>
<p><img loading="lazy" decoding="async" class="alignnone wp-image-487805" src="https://stage.unherd.com/wp-content/uploads/2023/10/ZoeApp.jpg" alt="" width="722" height="481" /></p>
<p>On social media, it doesn’t take long to find people posting about the thrill of receiving their ZOE test results. As one user, Joel, 28, said to us: “It gives you another thing to share on Facebook or Twitter.” But how much can we actually infer about what’s going on inside our bodies?</p>
<p>There has long been a temptation in medical circles to assume that the more biological parameters we measure, the better. The truth, however, is that not all test results are useful. Just because something is measurable in your body, doesn’t necessarily mean that the result will yield useful information.</p>
<p>Dr Guess claims the app might be doing little more than recommending more fruit and veg to everyone. “They have no published data showing all this info results in personalised dietary advice,” she says. “They need to show that the dietary recommendations made by their algorithm can be replicated by other scientists. In other words, does the test give the same dietary recommendations on Wednesday as it did on Monday? This is one of the hallmarks of good science. Even more important, they need to show what they’re doing actually improves a user’s short and long-term health.”</p>
<p>This isn’t to say that continuous glucose monitoring isn’t useful. It is offered in the NHS, but for specific reasons — for people with diabetes. Readings can help to adjust insulin doses and improve control of potentially harmful spikes and troughs. Many people say that it has revolutionised their care. In people without diabetes, however, blood glucose is under continuous physiological control — with the pancreas regulating the release and storage of sugar in the body to keep it within normal parameters. This is the market ZOE is aiming for.</p>
<p>They’re not the only company making continuous glucose monitors aimed at people without diabetes. Even those in the clinical medicine arena are pivoting into this space. Indeed, The Global Wellness Institute estimates the global market segment for “healthy eating, nutrition and weight loss” is worth $946 billion a year.</p>
<p>The only problem is we don’t really have any evidence that these monitors do keep non-diabetic people healthy.</p>
<p>Dr Shivani Misra, a consultant in metabolic medicine at Imperial College London who researches continuous glucose monitoring, cautions that we don’t totally understand how to interpret measurements in healthy people. “We have no robust evidence base to suggest that those rises and falls are signalling anything untoward in the present or that they have negative consequences in the future,” she says. In fact, different devices might have different readings in response to eating the same meal.</p>
<p>Dr Kevin Hall investigates the regulation of body weight and metabolism for the publicly funded US National Institutes of Health, which has a programme in precision nutrition. His team has studied the use of continuous glucose monitoring in highly controlled environments — when people actually live at the lab for a month and undergo very specific diets and exercise regimens. They measured the glucose levels of one person wearing two devices. They found that sometimes one of the devices would give a very high glucose reading after a meal, and the other would give a low reading. They also analysed readings on the same device. They changed the regimens week to week — and concluded that the response to the same meal might vary as much as it did to eating a different meal in different weeks.</p>
<p>“Even in these very highly regimented kinds of controlled feeding studies, they don&#8217;t give rise to reproducible measures,” Dr Hall says. “It&#8217;s very likely that if that person ate a banana the next week, even if they had exactly the same previous food and did the same exercise that day, they might get a very different response.”</p>
<p>Unsurprisingly, the results are causing confusion. For instance, Gail says her glucose levels went up when she was exercising and her friend, who has diabetes and is used to monitoring their glucose, looked at her graph and thought it looked high. “I felt I didn’t get enough explanation about what this means or what might happen to my glucose,” Gail says. On TikTok, users also warn against the unwanted “spike”, saying they need to get a flatter line and describing their worries about their glucose dipping at night.</p>
<p>But this is not necessarily something to worry about: glucose going up and down is a normal bodily response. “Any time they see a slight rise or spike, people panic and it’s creating unnecessary anxiety,” Dr Misra says. “Then they think it&#8217;s wrong to eat carbohydrates — which release glucose into the blood — and there is no evidence that this is necessary or beneficial. Some tell me it’s taken over their life.”</p>
<p><a name="data"></a><br />
<strong>4. Why ZOE wants your data</strong></p>
<p>But what about those who do feel their energy levels drop and notice a lethargic “crash”? Joel, for example, frequently wakes up at 3am to find his glucose dipping. He was even told he was waking up because of this dip. But he’s not entirely sure what to do about it.</p>
<p>This isn’t entirely surprising. While symptoms and how we feel are real, it can be hard to attribute cause and effect. In her clinic, Dr Misra sees people with and without diabetes who tell her they’re getting symptoms of low blood sugar, but when they’ve actually measured it, it’s within normal range. “There’s a risk everything becomes glucose-related,&#8221; Dr Misra says. “It’s human nature when you&#8217;re monitoring something you become hypervigilant about that.” This is something Dr Hall and his team also found in their studies. “I think the fascinating thing is that when people are provided with more and more information, they tend to make these correlations,” he says.</p>
<p>The risk is that we are creating problems for people rather than solving them, and turning healthy people into patients.</p>
<p>Ironically, perhaps mitigating this is the relationship between social class and health: in other words, the people most likely to be able to afford ZOE may be among the least likely to benefit from it. Because of this, Amitava Banerjee, professor of clinical data science at University College London and consultant cardiologist, says that ZOE plays into what is called the “digital divide”.</p>
<p>“Even when digital interventions are useful, the people who need them least are usually accessing them most, especially given the cost,” he says. “Those who are at the highest risk of health problems are often in more deprived and ethnically diverse areas, with neither the money nor the resources to use ZOE.&#8221; And even though it’s been largely tested on young healthy people of European ancestry — as the ZOE team has written in medical journals — the marketing goes beyond this cohort of people. “The results they get from studies might not be applicable to people outside that group,” Professor Bannerjee cautions.</p>
<p>Elsewhere, some doctors have turned to social media to complain about the increased workload the app is creating for them among a cohort known as the “worried well”. GPs have described to us how they’ve been contacted by patients concerned they have diabetes, as they think that is what their continuous glucose monitors are showing. While ZOE is just one of dozens of private companies and influencers who generate blood results capable of causing alarm and sending patients to NHS GPs, they all add pressure on appointments — especially if people didn’t get good enough information about what the test results actually mean.</p>
<p><a name="gut"></a><br />
<strong>5. What does your gut tell ZOE? </strong></p>
<p><img loading="lazy" decoding="async" class="aligncenter size-full wp-image-487849" src="https://stage.unherd.com/wp-content/uploads/2023/10/Dr-Tariq-Iqbal.jpg" alt="" width="1920" height="1080" /></p>
<p>Blood sugar is only a part of what ZOE tests. Other indicators as to the function of our metabolism and how we respond to food is determined by our gut microbiome. Zoe wants to harness the “potential power” of this to affect your long-term health and certain symptoms, and so takes a reading on how good your “gut bugs” are with the help of your stool sample. A diet plan to improve that is then constructed.</p>
<p>But not everyone is convinced there is sufficient scientific evidence to justify this approach. Dr Hall says research suggests you can change the microbiome in pretty consistent ways across individuals by changing their diet. “The complexity of the microbiome kind of belies a single readout of good versus bad. How you even come up with a single good, bad kind of criteria is mystifying to me,” he says.</p>
<p>Professor Tariq Iqbal, a gastroenterology consultant who runs trials into faecal microbiota transplantation in people who have bowel disorders, says that we’re only just beginning to understand to what degree levels of microbes naturally fluctuate in the gut in a healthy person over time. &#8220;At the moment, there is no reason to get your microbiome generally tested,” he says. “We don&#8217;t have good evidence about what a “normal” microbiome looks like. It&#8217;s more complicated than simply saying there are ‘bad’ and ‘good’ bacteria in the gut.”</p>
<p>Current research suggests that there is no “standard” microbiome composition that can be used as a baseline for health. There may also be problems with reading too much from a single sample. According to Guts UK, a digestive disease charity that works closely with the Gut Microbiome for Health Group of the British Society of Gastroenterology, the bacteria found in your stool does not necessarily tell you what microbes are in your gut. Meanwhile, the British Dietetic Association warns: “Commercial gut microbiota testing and lifestyle change programmes based on the test results cannot be advised currently as the science is not at a stage that can support testing and treatments programmes.”</p>
<p>Nor, Dr Guess adds, is there any robust evidence to support the claim that personalising a diet based on the gut microbiome is more effective than generic healthy eating advice for any of the claims being made. In fact, Professor Iqbal says that patients might be unnecessarily worried by what microbiome testing shows. “At the moment, we just do not have enough knowledge to safely and accurately recommend any specific interventions (such as particular changes in diet, and/or particular probiotics) to cause beneficial long-term changes to the composition of the bacteria in the gut,” Guts UK said.</p>
<p>ZOE, however, told us that their data showed members “who follow ZOE advice, including gut booster foods, see an improvement in their gut microbiome score” — the mix of “good” and “bad” microbes. This conclusion is drawn from a ZOE internal survey of 450 members who followed their advice for more than 12 weeks, which also showed 70% have more energy, 85% improved their gut health and others saw improvements in their menopause symptoms. This is all heavily promoted across their website.</p>
<p>These results haven’t been published and they declined to share it with us when we asked, so we are unable to assess what was asked or how the sample was selected. Moreover, as Dr Guess points out, “the data has not been validated or peer-reviewed”. <span style="font-weight: 400;">Neither was there a control group, which would be needed to know whether it was ZOEs’ specific advice, or simply better healthy eating, that was making a difference. </span><span style="font-weight: 400;">When we relayed this to ZOE, they </span><span style="font-weight: 400;">agreed this meant that we could not be sure these were “clinically meaningful results” and told us they were going to be publishing a randomised controlled trial in the future.</span></p>
<p><a name="scientific"></a><br />
<strong>6. How scientific is ZOE?</strong></p>
<p><img loading="lazy" decoding="async" class="aligncenter size-full wp-image-487850" src="https://stage.unherd.com/wp-content/uploads/2023/10/Dr-Shivani-Misra.jpg" alt="" width="1920" height="1080" /></p>
<p>It is hard not to be blown away by the dizzying array of high-profile journals that feature on ZOE’s website: <em>Nature Medicine</em>, <em>The BMJ</em>, <em>The Lancet</em>, among others. It links to abstracts of papers published in peer-reviewed journals, which on the surface seem to provide proof of the science. At a closer look, however, not all is as it seems.</p>
<p>ZOE places the weight of their programmes&#8217; claims on three main studies with the acronym PREDICT (Personalised Responses to Dietary Composition Trial). They were carried out with scientists from prestigious universities, including Stanford, Harvard and Kings’ College, London. They have not yet all been published.</p>
<p>The studies analyse the results of people making multiple readings about their body and food intake. This has produced a huge dataset: more than 4 million glucose readings so far, for example. These findings are then used to develop models to predict the impact of particular foods on our bodies — all valid areas of study. The researchers have searched for associations between different measurements, such as hunger and types of food eaten.</p>
<p>All of which sounds impressive. Until you realise that these were observational studies, which can only show <em>associations</em> between various data collected, and not causations, as Tim Spector himself has previously noted. For while measuring lots of variables to find patterns can be a useful research technique, it also means you increase the chances of finding coincidences — which puts you at risk of misinterpreting random variation as a meaningful difference. Poor practice in this type of study is known as “data dredging”.</p>
<p>Nor do they answer the key question: is there evidence that the individualised advice generated by the ZOE tests, which is the key market differentiator, does what it claims?</p>
<p>The answer: we don’t know. There have been no trials published exploring whether the “personalised” advice given by ZOE can result in better health outcomes compared with standard diet and lifestyle advice.</p>
<p>And the same holds for menopausal women, the key ZOE demographic targeted by Davina McCall. The first PREDICT study in 2022 compared data in pre, peri and postmenopausal women. According to ZOE: “Women who have been through menopause had, on average, higher blood pressure and blood sugar, a greater risk of developing cardiovascular disease in the next 10 years, worse sleep, and more body fat. Crucially, the team’s analysis found that diet and the bacterial species that were present in women’s guts were at least partially responsible for the changes.”</p>
<p>However, Dr David Nunan, Senior Research Fellow at the Centre for Evidence Based Medicine at the University of Oxford, is sceptical. &#8220;It&#8217;s a cross sectional [observational] study&#8221; he says, &#8220;which means that no claims of causation can be made.&#8221;</p>
<p>The design of the study, in other words, simply isn&#8217;t capable of telling whether any changes in the microbiome are a result of menopausal change. In fact, Dr Nunan says, “when the data for all microbiome species are compared, there is no statistical difference in pre and postmenopausal women. It’s only when you examine a subgroup of species that 8 out of 2,452 show a statistically significant difference.” Moreover, even when this happens, the study has not indicated what this means in real life. In other words, we do not know what impact this has for the ways that women metabolise food.</p>
<p>Yet despite these gaps, ZOE told us that they are “proud” to have recently completed their own randomised controlled trial “with a non-personalised control group versus the ZOE programme”. The full manuscript, they say, is “under preparation”.</p>
<p>According to its critics in the science community, however, even this trial has its design flaws. One group receives the whole ZOE package, the other receives a leaflet with US health advice. But the way it is set up, people will know exactly which group they are in, thereby rendering results less reliable. <span style="font-weight: 400;">A fairer test to assess is its ZOE’s personalised a</span><span style="font-weight: 400;">lgorithm</span><span style="font-weight: 400;"> that makes the difference would be for both groups to receive blood monitoring </span><span style="font-weight: 400;">and </span><span style="font-weight: 400;">stool analysis, and </span><span style="font-weight: 400;">what they thought was personalised advice. The only difference should be that one group receives advice based on ZOE’s tests and algorithms, while the other receives</span><span style="font-weight: 400;"> </span><span style="font-weight: 400;">advice</span><span style="font-weight: 400;"> that looks like it might be &#8220;personalised&#8221; but isn’t</span><span style="font-weight: 400;">.</span></p>
<p>“You have to bear in mind when looking at these studies that they aren’t fully independent,” Professor Banerjee says. “They are marking their own homework. You need external validation and testing to reproduce the results.”</p>
<p>None of this is to say that paying close attention to nutrition is not important. ZOE is only one of hundreds of apps that measure our biometrics in this age of the quantified self. But while keeping abreast of our data might be interesting, are these promises of personalised advice based on sound medicine? And are they, as the website promises, scientifically proven to lead to real-world improvements?</p>
<p>Without this evidence, Zoe is simply collecting our data and then selling it back to us. And not only does this come at a financial cost — it could be making us less healthy.</p>
<style>
				a.appcomments {
					background: #FFF;
					border: 1px solid #446c76 !important;
					font-family: benton-sans,sans-serif;
					font-weight: 600;
					font-style: normal;
					font-size: 12px;
					color: #446c76 !important;
					padding: 12px 50px;
					text-transform: uppercase;
					letter-spacing: 1.5px;
					text-decoration: none;
					width: 100%;
					display: block;
					text-align: center !important;
				 }
			</style>
			<a href="https://stage.unherd.com/2023/10/we-need-to-talk-about-zoe/?edition=us?appcomments" class="appcomments">view comments</a>]]>
							</content:encoded>
																<unherd:comments_embed_url>https://stage.unherd.com/2023/10/we-need-to-talk-about-zoe/?edition=us?appcommentsnew</unherd:comments_embed_url>
											<wfw:commentRss>https://stage.unherd.com/2023/10/we-need-to-talk-about-zoe/?edition=us/feed/</wfw:commentRss>
															<post-id xmlns="com-wordpress:feed-additions:1">481727</post-id>				</item>
						</channel>
</rss>
